US healthcare giant Johnson & Johnson today said it would spend up to USD 200 million to speed up and expand its Ebola vaccine program with testing slated to begin in January. Johnson & Johnson said its unit Janssen Pharmaceutical Companies was closely working with the World Health Organization the National Institute of Allergy and Infectious Diseases as well as other key stakeholders governments and public health authorities on the program. The proposed vaccine regimen combines a Janssen preventative vaccine with a vaccine from Bavarian Nordic a biotechnology company based in Denmark. The vaccine combination was discovered in a collaborative